Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merrion, Rebel Enter Feasibility and Option Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merrion, Rebel Enter Feasibility and Option Agreement

Merrion Pharmaceuticals has entered an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC to evaluate the ability of its GIPET technology to boost the bioavailablity of three undisclosed compounds.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merrion Pharmaceuticals has entered an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC to evaluate the ability of its GIPET technology to boost the bioavailablity of three undisclosed compounds. Following the feasibility studies, the Rebel will have the option to enter into a licensing agreement for Merrion’s GIPET technology. Financial terms were not disclosed.

John Lynch, chief executive officer, Merrion Pharmaceuticals said, “We are very pleased to be entering into this agreement with one of the world’s leading pharmaceutical companies to assess the ability of our unique GIPET technology to substantially improve the product profile of three of their compounds. This agreement is further validation of the broad applicability of our GIPET technology and the high level of interest in using the power of GIPET in the pharmaceutical industry.”

David Blume, chief executive officer, Rebel Pharmaceuticals, commented, “we are excited to partner with Merrion Pharmaceuticals to use their GIPET technology to achieve our goals for these development programs of enhancing existing drugs to benefit patients.”

Merrion’s GIPET technology platform covers a wide range of compounds with varying physiochemical properties and molecular weights. According to the company, GIPET has shown the ability to improve absorption by as much as 200 times, achieving greater intersubject reproducibility with a positive safety database.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics